An outbreak of e-cigarette, or vaping, associated lung injury (EVALI) was noted in the USA starting in March of 2019 [1]. Although there have been prior reports of various lung diseases associated with e-cigarette use since they first came on the market in 2011 [2], the outbreak this summer was remarkable in the large number of patients affected (2409 reported hospitalised with 52 deaths as of 13 December, 2019 in the USA alone [1]) and the severity of lung injury. Although e-cigarette use is quite common in Europe [3], to date no cases of EVALI that developed in Europe have been reported. Questions regarding the geographic distribution of EVALI in the context of the global distribution and use of e-cigarettes have been raised. The first case of e-cigarette, or vaping, associated lung injury (EVALI) diagnosed and treated in Europe reminds us to remain vigilant for this diagnosis, and importantly, that we are still learning about the full spectrum of risks of e-cigarette use http://bit.ly/2TauItr

中文翻译：

---

没有人是一座孤岛：欧洲的电子烟或电子烟相关肺损伤

从 2019 年 3 月开始，美国爆发了电子烟或电子烟相关肺损伤 (EVALI) [1]。尽管自 2011 年电子烟首次上市以来，已有各种与使用电子烟相关的肺部疾病的先前报道[2]，但今年夏天的爆发在受影响的患者人数众多（据报道有 2409 人住院，其中 52 人死亡为2019 年 12 月 13 日仅在美国 [1]) 和肺损伤的严重程度。尽管电子烟的使用在欧洲相当普遍 [3]，但迄今为止，尚未报告在欧洲发生的 EVALI 病例。在电子烟全球分布和使用的背景下，关于 EVALI 的地理分布的问题已经被提出。电子烟的第一例，或vaping，